August 21, 2017
The Third Circuit on Monday handed a sweeping victory to buyers of cholesterol drug Lipitor and antidepressant drug Effexor XR, reviving their antitrust claims for alleged patent fraud and anti-competitive reverse payment schemes.
May 18, 2017
The Third Circuit will hear oral arguments Friday in a pair of pay-for-delay cases over the drugs Lipitor and Effexor that could heighten the standard needed to allege that agreements to settle pharmaceutical patent dispute litigation constitute so-called reverse payments that run afoul of antitrust law.
April 13, 2017
The Third Circuit on Thursday said it has jurisdiction to consider the merits of two appeals of lower court dismissals of alleged pay-for-delay litigation over the drugs Lipitor and Effexor XR, rejecting calls by the pharmaceutical companies involved in the cases to transfer them to the Federal Circuit.
September 27, 2016
Drugmakers Wyeth and Teva told the Third Circuit that purchasers’ claims of a reverse payment scheme over the generic version of the antidepressant Effexor XR belonged before the Federal Circuit, in the second case heard by the appeals court Tuesday on pay-for-delay jurisdictional issues.